Skip to content

Study · Animal study (in vivo) · rat and guinea pig · 2016

6 results

NO system dependence of atropine-induced mydriasis and L-NAME- and L-arginine-induced miosis: Reversal by the pentadecapeptide BPC 157 in rats and guinea pigs.

Kokot A, Zlatar M, Stupnisek M, Drmic D, Radic R, Vcev A, Seiwerth S, Sikiric P

European journal of pharmacology15 Dec 2015Cited by 30 (Europe PMC)

PMID26698393 (opens in a new tab)DOI10.1016/j.ejphar.2015.12.016 (opens in a new tab)PepBankPUB-26698393
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats and guinea pigs, BPC‑157 alone did not affect normal pupils in any regimen.

    In plain wordsIn rats and guinea pigs, BPC‑157 alone did not change normal pupils.

    Peptide
    BPC-157
    Outcome
    No significant changeNormal pupil response to BPC 157 alone
    Study

    rat and guinea pign: not reported in source

    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    0.4 µg/eye; 10 µg, 10 ng, 10 pg/kg · local eye drops or intraperitonealAs given in this study (rat and guinea pig).

    Source sentences

    Summary
    Always, BPC 157 alone (both species; locally; systemically; all regimens) did not affect normal pupils.
    1 context sentence
    Summary · context
    We administered locally (two drops/eye) or systemically (intraperitoneally/kg) [BPC 157 (0.4µg/eye; 10µg, 10ng, 10pg/kg), L-NAME (0.1mg/eye; 5mg/kg), and L-arginine (2mg/eye; 100mg/kg) alone and combined] at 3min prior to assessment (normal pupils) or alternatively at maximal 1% atropine-induced myd…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats and guinea pigs with atropine-induced mydriasis, BPC‑157 alone counteracted the pupil dilation.

    In plain wordsIn rats and guinea pigs with atropine-widened pupils, BPC‑157 alone counteracted the widening.

    Peptide
    BPC-157
    Outcome
    DecreaseAtropine-induced mydriasis
    Study

    rat and guinea pign: not reported in source

    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    0.4 µg/eye; 10 µg, 10 ng, 10 pg/kg · local eye drops or intraperitonealAs given in this study (rat and guinea pig).

    Source sentences

    Summary
    BPC 157 alone counteracted atropine-induced mydriasis.
    1 context sentence
    Summary · context
    We administered locally (two drops/eye) or systemically (intraperitoneally/kg) [BPC 157 (0.4µg/eye; 10µg, 10ng, 10pg/kg), L-NAME (0.1mg/eye; 5mg/kg), and L-arginine (2mg/eye; 100mg/kg) alone and combined] at 3min prior to assessment (normal pupils) or alternatively at maximal 1% atropine-induced myd…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats and guinea pigs with atropine-induced mydriasis, BPC‑157 augmented the counteracting effects of L-NAME, L-arginine and their combination, with few exceptions.

    In plain wordsIn rats and guinea pigs with atropine-widened pupils, BPC‑157 mostly strengthened the narrowing effects of L-NAME and L-arginine.

    Peptide
    BPC-157
    Outcome
    IncreaseAugmentation of L-NAME and L-arginine effects on atropine mydriasis
    Study

    rat and guinea pign: not reported in source

    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    0.4 µg/eye; 10 µg, 10 ng, 10 pg/kg · local eye drops or intraperitonealAs given in this study (rat and guinea pig).

    Source sentences

    Summary
    With few exceptions (when administered with L-NAME or L-arginine or L-NAME+L-arginine), BPC 157 augments their counteracting effects.
    1 context sentence
    Summary · context
    We administered locally (two drops/eye) or systemically (intraperitoneally/kg) [BPC 157 (0.4µg/eye; 10µg, 10ng, 10pg/kg), L-NAME (0.1mg/eye; 5mg/kg), and L-arginine (2mg/eye; 100mg/kg) alone and combined] at 3min prior to assessment (normal pupils) or alternatively at maximal 1% atropine-induced myd…
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats and guinea pigs, BPC‑157 prolonged L-arginine-induced miosis, with specific exceptions.

    In plain wordsIn rats and guinea pigs, BPC‑157 made the pupil narrowing caused by L-arginine last longer, with some exceptions.

    Peptide
    BPC-157
    Outcome
    IncreaseDuration of L-arginine-induced miosis
    Study

    rat and guinea pign: not reported in source

    Comparator
    L-arginine without BPC 157
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    0.4 µg/eye; 10 µg, 10 ng, 10 pg/kg · local eye drops or intraperitonealAs given in this study (rat and guinea pig).

    Source sentences

    Summary
    Despite specific exceptions, BPC 157 distinctively affects L-arginine-miosis (prolongation)
    1 context sentence
    Summary · context
    We administered locally (two drops/eye) or systemically (intraperitoneally/kg) [BPC 157 (0.4µg/eye; 10µg, 10ng, 10pg/kg), L-NAME (0.1mg/eye; 5mg/kg), and L-arginine (2mg/eye; 100mg/kg) alone and combined] at 3min prior to assessment (normal pupils) or alternatively at maximal 1% atropine-induced myd…
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats and guinea pigs, BPC‑157 shortened L-NAME-induced miosis, with specific exceptions.

    In plain wordsIn rats and guinea pigs, BPC‑157 shortened the pupil narrowing caused by L-NAME, with some exceptions.

    Peptide
    BPC-157
    Outcome
    DecreaseDuration of L-NAME-induced miosis
    Study

    rat and guinea pign: not reported in source

    Comparator
    L-NAME without BPC 157
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    0.4 µg/eye; 10 µg, 10 ng, 10 pg/kg · local eye drops or intraperitonealAs given in this study (rat and guinea pig).

    Source sentences

    Summary
    Despite specific exceptions, BPC 157 distinctively affects L-arginine-miosis (prolongation) and L-NAME-miosis (shortening).
    1 context sentence
    Summary · context
    We administered locally (two drops/eye) or systemically (intraperitoneally/kg) [BPC 157 (0.4µg/eye; 10µg, 10ng, 10pg/kg), L-NAME (0.1mg/eye; 5mg/kg), and L-arginine (2mg/eye; 100mg/kg) alone and combined] at 3min prior to assessment (normal pupils) or alternatively at maximal 1% atropine-induced myd…
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats and guinea pigs, adding BPC‑157 to L-NAME plus L-arginine made the effect on the pupil less pronounced.

    In plain wordsIn rats and guinea pigs, adding BPC‑157 to L-NAME plus L-arginine made the pupil effect less pronounced.

    Peptide
    BPC-157
    Outcome
    DecreaseMiosis with L-NAME plus L-arginine plus BPC 157
    Study

    rat and guinea pign: not reported in source

    Comparator
    L-NAME plus L-arginine
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    0.4 µg/eye; 10 µg, 10 ng, 10 pg/kg · local eye drops or intraperitonealAs given in this study (rat and guinea pig).

    Source sentences

    Summary
    When L-arginine and L-NAME were combined (L-NAME+L-arginine+BPC 157), the effect was less pronounced.
    1 context sentence
    Summary · context
    We administered locally (two drops/eye) or systemically (intraperitoneally/kg) [BPC 157 (0.4µg/eye; 10µg, 10ng, 10pg/kg), L-NAME (0.1mg/eye; 5mg/kg), and L-arginine (2mg/eye; 100mg/kg) alone and combined] at 3min prior to assessment (normal pupils) or alternatively at maximal 1% atropine-induced myd…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.